Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00062816
Recruitment Status : Completed
First Posted : June 18, 2003
Last Update Posted : October 17, 2007
Information provided by:
Ionis Pharmaceuticals, Inc.

Brief Summary:
The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard therapy or still have detectable HCV at Week 24.

Condition or disease Intervention/treatment Phase
Hepatitis C, Chronic Drug: ISIS 14803, peginterferon alfa, ribavirin Phase 1 Phase 2

Detailed Description:

Previously untreated chronic hepatitis C patients undergoing therapy with peginterferon alfa and ribavirin have a very poor probability of achieving a sustained virologic response if they either do not have a 100-fold or greater reduction in their plasma HCV RNA levels at the 12th week of treatment or have detectable plasma HCV RNA at the 24th week of treatment. ISIS 14803 is an experimental antiviral medication for the treatment of chronic hepatitis C that has been given to chronic hepatitis C patients in two previous single-agent clinical trials (approximately 70 patients).

In this clinical research study, 12 weeks of ISIS 14803 treatment will be added to the peginterferon alfa and ribavirin treatment regimen of previously untreated chronic hepatitis C patients who have a very poor probability of achieving a sustained virologic response based upon either of the above two criteria. Enrolled patients must continue to be treated with peginterferon alfa and ribavirin and must begin ISIS 14803 treatment within four weeks of their HCV RNA result report date. ISIS 14803 will be given as a two-hour intravenous infusion, two times each week, for 12 weeks. Depending on their HCV response to the three-drug combination, patients may continue treatment with peginterferon alfa and ribavirin after the end of ISIS 14803 treatment. Patients will be monitored for at least eight weeks (for safety) after the end of ISIS 14803 treatment and possibly for longer (for sustained virologic response). Two dose levels of ISIS 14803 will be studied in this trial, 3 and 6 mg/kg ideal body weight.

Study Type : Interventional  (Clinical Trial)
Enrollment : 22 participants
Primary Purpose: Treatment
Study Start Date : May 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Ribavirin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria (partial list):

  • Age 18 to 65 years.
  • Infection with HCV.
  • Prior liver biopsy indicating chronic hepatitis.
  • Received at least 12 weeks of continuous peginterferon alfa and ribavirin therapy.
  • HCV infection was untreated prior to current peginterferon alfa and ribavirin regimen.
  • Either less than 100-fold reduction in plasma or serum HCV RNA despite receiving 12 weeks of peginterferon alfa and ribavirin therapy or detectable HCV RNA at week 24 of therapy.
  • Prothrombin time and aPTT within normal reference range.
  • Serum bilirubin concentration within normal reference range.
  • Give written informed consent to participate in the study.

Exclusion criteria (partial list):

  • Pregnant women or nursing mothers or women of childbearing potential without adequate contraception.
  • Systemic corticosteroid therapy within 3 months of screening.
  • Serum ALT greater than 5 x upper limit of normal range.
  • HIV or HBV infection.
  • Decompensated liver disease.
  • Evidence of cirrhosis.
  • Severe depression with suicidal ideation requiring hospitalization within one year of screening.
  • Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin.
  • Any condition which, in the opinion of the Investigator, would preclude participation in or interfere with compliance.
  • Alcohol or drug abuse.
  • Is undergoing or has undergone treatment with another investigational drug, biologic agent or device within 30 days of screening
  • History of cryoglobulinemia or vasculitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00062816

  Show 25 Study Locations
Sponsors and Collaborators
Ionis Pharmaceuticals, Inc. Identifier: NCT00062816     History of Changes
Other Study ID Numbers: ISIS 14803-CS3
First Posted: June 18, 2003    Key Record Dates
Last Update Posted: October 17, 2007
Last Verified: October 2007

Keywords provided by Ionis Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents